Renalytix Announces That The US Patent Office Has Issued A New Notice Of Allowance Of Claims Surrounding The Biomarkers STNFR1 And STNFR2 Used In The Kidneyintelx.dkd Test
Portfolio Pulse from Benzinga Newsdesk
Renalytix has announced that the US Patent Office has issued a new notice of allowance of claims surrounding the biomarkers STNFR1 and STNFR2 used in the KidneyIntelX.DKD test.
October 06, 2023 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Renalytix's new patent allowance for biomarkers used in KidneyIntelX.DKD test could strengthen its product portfolio and potentially increase its market share.
The new patent allowance for Renalytix's biomarkers used in the KidneyIntelX.DKD test could potentially enhance the company's product portfolio and competitive advantage. This could lead to increased market share and revenues, positively impacting the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100